A federal judge dismissed United Therapeutics’ (UTHR) cross-claims against Liquidia (LQDA) and the Food and Drug Administration, allowing Liquidia’s Yutrepia to move forward for a launch as early as this month, Christopher Yasiejko and Nyah Phengsitthy of Bloomberg report. The ruling means Liquidia’s lung disease drug can receive final approval and launch when United ‘s exclusivity for the dry-powder-inhalation version of Tyvaso expires on May 23, according to Bloomberg. Shares of Liquidia are up 12%, or $1.72, to $15.70 in afternoon trading. Scotiabank called the ruling a “best case scenario” for Liquidia ahead of Yutrepia’s FDA action date on May 24.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia price target raised at Scotiabank after ‘best case’ court ruling
- Legal Victory and Favorable Market Outlook Boost Liquidia Technologies to Buy Rating
- Liquidia up 13% to $15.85 in afternoon trading
- Strategic Legal Actions and Market Positioning Drive Buy Rating for Liquidia Technologies
- Liquidia Technologies: Buy Rating Affirmed Amidst Transformative Opportunities and Strategic Growth Potential
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue